FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78346
News■ Unclear/unknown
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
KINDNews
DIRECTION■ Unclear/unknown
SOURCES6
ENTITIES1
STORY SIZE7 RECORDS
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Law-firm solicitation about insider fiduciary duties signals potential shareholder litigation but names no verified misconduct.
Attorney ad, not evidence of wrongdoing
CATALYST TO WATCH
Actual lawsuit filing or disclosure
MAIN RISK
Unfounded claim spooks holders
FULL DISPATCH
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 7 TIMES · FIRST · LAST2026-09-26 03:16 UTCNewsDid PACS Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-09-26 05:45 UTCNewsDid Zeta Global Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
2026-10-13 18:50 UTCNewsDid Sprout Social, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-10-13 18:52 UTCNewsDid Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?CURRENT RECORD
2026-10-13 19:01 UTCNewsDid Perpetua Resources Corp. Insiders Breach their Fiduciary Duties to Shareholders?
2026-10-13 19:04 UTCNewsDid Zeta Global Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
2026-10-13 19:05 UTCNewsDid Monolithic Power Systems, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
FTC Seeks Sanctions Against Shkreli Over Alleged Pharma Ban Breaches2026-10-13 18:42 UTC
FTC Seeks Sanctions Against Shkreli Over Alleged Pharma Ban Breaches2026-10-13 18:42 UTC
→CORRELATIONshares Healthcare
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease2026-10-13 19:15 UTC
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease2026-10-13 19:15 UTC
→CORRELATIONshares Healthcare
Social Security benefits are rising again, but probably not enough to offset healthcare costs2026-10-13 19:26 UTC
Social Security benefits are rising again, but probably not enough to offset healthcare costs2026-10-13 19:26 UTC
→CORRELATIONshares Healthcare
Kimberly-Clark’s $40 Billion Kenvue Takeover Clears EU Antitrust Review2026-10-13 19:02 UTC
Kimberly-Clark’s $40 Billion Kenvue Takeover Clears EU Antitrust Review2026-10-13 19:02 UTC
→CORRELATIONshares Healthcare
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)2026-10-13 19:36 UTC
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)2026-10-13 19:36 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.